ULTRAGENYX PHARMACEUTICAL INC. Deferred Foreign Income Tax Expense (Benefit)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Deferred Foreign Income Tax Expense (Benefit) of $1.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. deferred foreign income tax expense (benefit) for fiscal 2024 was $1.00M, a 536.94% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. deferred foreign income tax expense (benefit) for fiscal 2023 was $157.00K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month | Deferred Foreign Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-12-31 | $1.00M 10-K · filed 2026-02-18 | $1.37M 10-K · filed 2025-02-19 |
| 2023-12-31 | $157.00K 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |